ARROWHEAD PHARMACEUTICALS, INC.

Listed Company

ARWRCIK 0000879407NasdaqLarge AcceleratedPharmaceutical PreparationsDelawareFY ends Sep 30

Period

FY 2025

Revenue

$829.45M

Net Income

$-1.63M

Total Assets

$1.39B

Equity

$466.05M

Shares Out

140.03M

Op. Cash Flow

$179.55M

Business

ARROWHEAD PHARMACEUTICALS, INC. develops medicines that treat intractable diseases by silencing disease-causing genes using RNA interference (RNAi) technologies. It designs and delivers siRNA therapeutics and related RNA chemistries via its proprietary TRiM platform, with an approved siRNA product and multiple clinical-stage and discovery-stage candidates. The company organizes activities across discovery, preclinical and clinical development, manufacturing and commercial operations, and enters licensing and collaboration agreements for partnered programs. It pursues regulatory approvals and clinical trials across the United States, the European Union and other international markets while leveraging partner commercialization channels worldwide.

Summary from filing dated 2025-11-25

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-09-30	FY 2024 2024-09-30	FY 2023 2023-09-30	FY 2022 2022-09-30	FY 2021 2021-09-30
Revenue	829	4	241	243	138
Research and development	607	506	353	—	—
General and administrative	124	99	93	124	81
Total operating expenses	731	605	446	422	287
Operating income (loss)	98	−601	−205	−179	−149
Interest income	37	23	15	5	6
Interest expense	−89	−32	−18	0	—
Other, net	5	−2	2	765,000	2
Total other expense	−47	−11	−1	6	8
Income (loss) before income tax expense and noncontrolling interest	52	−612	−206	−173	−141
Income tax expense (benefit)	21	−3	3	4	2,000
Net income (loss) including noncontrolling interest	30	−610	−209	−176	−141
Net income (loss) attributable to noncontrolling interest, net of tax	32	−10	−4	−431,000	0
Net loss attributable to Arrowhead Pharmaceuticals, Inc.	−2	−599	−205	−176	−141
Basic (in dollars per share)	−0.01	−5	−1.92	−1.67	−1.36
Diluted (in dollars per share)	−0.01	−5	−1.92	−1.67	−1.36
Basic (in shares)	134	120	107	105	104
Diluted (in shares)	134	120	107	105	104
Unrealized gains (losses) on available-for-sale securities	2	4	−3	0	0
Foreign currency translation adjustments	−432,000	4	−122,000	−67,000	−87,000
Comprehensive income (loss) attributed to noncontrolling interest	32	−10	−4	—	—
Other comprehensive income (loss)	32	−602	−212	−177	−141

Consolidated Balance Sheet

As of · In millions, except per-share amounts

Concept	FY 2025 2025-09-30	FY 2024 2024-09-30	FY 2023 2023-09-30	FY 2022 2022-09-30	FY 2021 2021-09-30
Cash, cash equivalents and restricted cash	227	103	111	108	184
Accounts receivable	7	0	0	1	10
Available-for-sale securities, at fair value	693	578	293	0	—
Prepaid expenses	11	10	9	7	4
Other current assets	14	5	4	20	2
Total current assets	951	695	416	405	385
Property, plant and equipment, net	383	386	290	110	49
Intangible assets, net	7	9	10	12	14
Right-of-use assets	44	45	45	58	17
Other assets	1	4	3	218,000	272,000
Total Assets	1,385	1,140	766	692	710
Accounts payable	18	11	36	3	9
Accrued expenses	90	63	40	47	14
Accrued payroll and benefits	27	22	18	12	10
Lease liabilities	7	6	11	3	2
Deferred revenue	2	0	866,000	74	111
Credit facility	40	0	—	—	—
Other liabilities	11	432,000	435,000	0	—
Total current liabilities	195	103	105	139	147
Lease liabilities, net of current portion	104	111	105	79	23
Liability related to the sale of future royalties	367	341	268	0	—
Credit facility, net of current portion	215	393	0	—	—
Total long-term liabilities	686	846	373	135	155
Commitments and contingencies (Note 7)	—	—	—	—	—
Common stock, $0.001 par value: Authorized 290,000 shares; issued and outstanding 135,702 and 124,376 shares at September 30, 2025 and 2024, respectively	231,000	217,000	200,000	198,000	197,000
Additional paid-in capital	2,140	1,806	1,300	1,219	1,053
Accumulated other comprehensive income	6	5	−3	−136,000	−69,000
Accumulated deficit	−1,627	−1,626	−1,026	−821	−645
Treasury stock; at cost; 2,661 and 0 shares of common stock at September 30, 2025 and 2024, respectively	−53	0	—	—	—
Total Arrowhead Pharmaceuticals, Inc. stockholders' equity	466	185	271	399	409
Noncontrolling interest	37	6	16	20	0
Total noncontrolling interest and stockholders' equity	503	191	287	418	409
Total Liabilities, Noncontrolling Interest and Stockholders' Equity	1,385	1,140	766	692	710

Consolidated Statement of Cash Flows

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-09-30	FY 2024 2024-09-30	FY 2023 2023-09-30	FY 2022 2022-09-30	FY 2021 2021-09-30
Stock-based compensation	63	74	78	121	77
Depreciation and amortization	24	19	12	10	8
Accretion of note premiums/discounts	−6	−3	−2	3	266,000
Non-cash interest expense on liability related to the sale of future royalties	26	23	18	—	—
Non-cash interest expense on credit facility	63	9	0	0	—
Non-cash gain on treasury stock received	−3	0	0	—	—
Realized loss on investments	0	80,000	0	4	—
Accounts receivable	−57	0	1	9	−9
Prepaid expenses and other current assets	−10	−2	12	−19	−360,000
Accounts payable	6	−6	33	−7	3
Accrued expenses	41	32	−15	18	10
Deferred revenue	2	−866,000	−129	−113	223
Operating lease, net	−5	2	47	13	3
Other	3	−1	0	—	—
Net cash provided by (used in) operating activities	180	−463	−154	−136	171
Purchases of property, plant and equipment	−23	−141	−177	−53	−24
Purchases of investments	−796	−721	−246	−223	−241
Proceeds from sales and maturities of investments	690	442	327	271	123
Net cash used in investing activities	−129	−420	−96	−5	−142
Proceeds from the exercises of stock options	4	2	3	5	11
Proceeds from the issuance of common stock, net of offering costs	241	429	0	0	0
Proceeds from the sale of future royalties	0	50	250	0	0
Proceeds from the issuance of warrants	25	0	0	—	—
Payment of debt issuance costs	−5	−3	0	0	—
Proceeds from credit facility	0	392	0	0	—
Repayments of credit facility	−202	0	0	—	—
Proceeds from Visirna credit agreement	10	0	0	—	—
Net cash provided by financing activities	74	871	253	65	11
Net increase (decrease) in cash, cash equivalents and restricted cash	124	−12	3	−76	41
Effect of exchange rate on cash, cash equivalents and restricted cash	−401,000	4	−122,000	−67,000	−88,000
Interest paid	−19,000	0	0	0	0
Income taxes (refund) paid	814,000	−4	0	−2,000	−2,000
Treasury stock received to settle accounts receivable	50	0	0	—	—
Capital expenditures included in accrued expenses	277,000	4	14	18	—

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro